Shingo Nishikawa

High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer

Ryo Ariyasu, Shingo Nishikawa, Ken Uchibori et al. · Lung Cancer · 2018 · 53 citations

Medicine, Oncology, Pharmacology +17

Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy

Ryo Ariyasu, Atsushi Horiike, Takahiro Yoshizawa et al. · Anticancer Research · 2017 · 50 citations · Full text

Medicine, Endocrinology, Internal Medicine +16

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms

Noriko Yanagitani, Ken Uchibori, Sumie Koike et al. · Cancer Science · 2020 · 48 citations · Full text

Medicine, Oncology, Pharmacology +15

Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995–2017

Natsuki Takano, Ryo Ariyasu, Junji Koyama et al. · Lung Cancer · 2019 · 43 citations

Medicine, Oncology, Surgery +11

Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non–Small-Cell Lung Cancer and High PD-L1 Tumor Expression

Yuichi Tambo, Takashi Sone, Kazuhiko Shibata et al. · Clinical Lung Cancer · 2020 · 36 citations

Medicine, Oncology, Pharmacology +16